Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...
Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization
Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several...
MSD China to Take Legal Action Against Market Infringement of Molnupiravir
Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...
Med Vision Secures Series A+ Funding to Expand Digital Therapy Portfolio
Med Vision, a Hangzhou-based digital therapy specialist, has reportedly raised “tens of millions” of renminbi...
Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution
China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...
Bioantibody Bio Raises RMB 100 Million in Series A Funding Round
Bioantibody Biotechnology Co., Ltd, a Nanjing-based in vitro diagnostics (IVD) and biologic company, has reportedly...
Meihua Partners with Getein Biotech to Manufacture COVID-19 Antigen Tests
China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with...
CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
China’s Dental Implant VBP Tender Results in Significant Price Cuts
The results of the dental implant system-focused volume-based procurement (VBP) tender held in Sichuan have...
Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...
MediTrust Health Secures Series C+ Funding with HSBC as Strategic Investor
MediTrust Health, the insurance, financing, and direct-to-patient pharmacy subsidiary of China-based Shanghai Pharmaceuticals Holding Co.,...
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...
Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics
China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc.,...
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...
HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges
The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022,...
Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open,...
Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...